In the present study, we present data suggesting that CTLA4-FasL naturally forms a stable and soluble homo-hexamer and propose a unique mode-of-action model for the treatment of B cell lymphoma. Here, CTLA4 is linked to B-cell non-Hodgkin lymphoma.